890709-17-8

Basic information

• Product Name: tert-butyl 4-quinolin-2-ylpiperazine-1-carboxylate
• Synonyms: tert-butyl 4-quinolin-2-ylpiperazine-1-carboxylate
• CAS NO: 890709-17-8
• Molecular Formula: C18H23N3O2
• Molecular Weight: 313.39412
• EINECS: -0
• Mol File: 890709-17-8.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 4-quinolin-2-ylpiperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-quinolin-2-ylpiperazine-1-carboxylate(890709-17-8)
• EPA Substance Registry System: tert-butyl 4-quinolin-2-ylpiperazine-1-carboxylate(890709-17-8)

Safety Data

• Hazardous Substances Data: 890709-17-8(Hazardous Substances Data)

Usage

Uses

tert-Butyl 4-(Quinolin-2-yl)piperazine-1-carboxylate is used as a reactant in the preparation of benzothiazole derivatives and other heterocyclic compounds as PPAR agonists.

Upstream product

• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 77278-40-1 tert-butyl 4-(benzoyloxy)piperazine-1-carboxylate 
• 2005-43-8 2-bromoquinoline 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 612-62-4 2-Chloroquinoline 

Downstream Products

• 4774-24-7 2-(piperazin-1-yl)quinoline 
• 1245646-84-7 2-(1-piperazinyl)quinoline hydrochloride 

Relevant articles and documents

Inhibition of Yeast-to-Hypha Transition and Virulence of Candida albicans by 2-Alkylaminoquinoline Derivatives

A rapid increase in Candida albicans infection and drug resistance has caused an emergent need for new clinical strategies against this fungal pathogen. In this study, we evaluated the inhibitory activity of a series of 2-alkylaminoquinoline derivatives against C. albicans isolates. A total of 28 compounds were assessed for their efficacy in inhibiting the yeast-to-hypha transition, which is considered one of the key virulence factors in C. albicans. Several compounds showed strong activity to decrease the morphological transition and virulence of C. albicans cells. The two leading compounds, compound 1 (2-[piperidin-1-yl]quinolone) and compound 12 (6-methyl-2-[piperidin-1-yl]quinoline), remarkably attenuated C. albicans hyphal formation and cytotoxicity in a dose-dependent manner, but they showed no toxicity to either C. albicans cells or human cells. Intriguingly, compound 12 showed an excellent ability to inhibit C. albicans infection in the mouse oral mucosal infection model. This leading compound also interfered with the expression levels of hypha-specific genes in the cyclic AMP-protein kinase A and mitogen-activated protein kinase signaling pathways. Our findings suggest that 2-alkylaminoquinoline derivatives could potentially be developed as novel therapeutic agents against C. albicans infection due to their interference with the yeast-to-hypha transition.

Discovery of imidazole carboxamides as potent and selective CCK1R agonists

High-throughput screening revealed diaryl pyrazole 3 as a selective albeit modest cholecystokinin 1 receptor (CCK1R) agonist. SAR studies led to the discovery and optimization of a novel class of 1,2-diaryl imidazole carboxamides. Compound 44, which was profiled extensively, showed good in vivo mouse gallbladder emptying (mGBE) and lean mouse overnight food intake (ONFI) reduction activities.